CoChat

Randomized Trial of Micafungin for the Prevention of Invasive Fungal Infection in High-Risk Liver Transplant Recipients

Open access
Saliba, Faouzi, Pascher, Andreas, Cointault, Olivier, Laterre, Pierre-François, Cervera, Carlos, De Waele, Jan J., Cillo, Umberto, Langer, Róbert M., Lugano, Manuela, Göran-Ericzon, Bo, Phillips, Stephen, Tweddle, Lorraine, Karas, Andreas, Brown, Malcolm, Fischer, Lutz, for the TENPIN (Liver Transplant European Study Into the Prevention of Fungal Infection) Investigators, Pratschke, Johann, Decruyenaere, Johan, De Waele, Jan J., Laterre, Pierre-François, Moreno, Christophe, Michielsen, Peter, Cointault, Olivier, Fischer, Lutz, Neuhaus, Peter, Pascher, Andreas, Schemmer, Peter, Cervera, Carlos, Varo, Evaristo, Montejo, Miguel, Bouza, Emilio, Blanes, Marino, De La Torre, Julián, Fortun, Jesus, Saliba, Faouzi, Rostaing, Lionel, Paugam-Burtz, Catherine, Eyraud, Daniel, Shah, Tahir, Heaton, Nigel, Langer, Róbert M., McCormick, Aiden, Cillo, Umberto, Salizzoni, Mauro, Lugano, Manuela, De Gasperi, Andrea, Tomé, Luís, Daniel, Jorge, Popescu, Irinel, Moysyuk, Yan G., Chzhao, Alexey V., Zagaynov, Vladimir E., Ericzon, Bo-Göran · 2015 · Clinical Infectious Diseases
Cited by 82

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Invasive fungal infection (IFI) following liver transplant is associated with significant morbidity and mortality. Antifungal prophylaxis is rational for liver transplant patients at high IFI risk. METHODS: In this open-label, noninferiority study, patients were randomized 1:1 to receive intravenous micafungin 100 mg or center-specific standard care (fluconazole, liposomal amphotericin B, or caspofungin) posttransplant. The primary endpoint was clinical success (absence of a proven/probable IFI and no need for additional antifungals) at end of prophylaxis (EOP). Noninferiority (10% margin) of micafungin vs standard care was assessed in the per protocol and full analysis sets. Safety assessments included adverse events and liver and kidney function tests. RESULTS: The full analysis set comprised 344 patients (172 micafungin; 172 standard care). Mean age was 51.2 years; 48.0% had a Model for End-Stage Liver Disease score ≥20. At EOP (mean treatment duration, 17 days), clinical success was 98.6% for micafungin and 99.3% for standard care (Δ standard care - micafungin [95% confidence interval], 0.7% [-2.7% to 4.4%]) in the per protocol set and 96.5% and 93.6%, respectively (-2.9% [-8.0% to 1.9%]), in the full analysis set. Incidences of drug-related adverse events for micafungin and standard care were 11.6% and 16.3%, leading to discontinuation in 6.4% and 11.6% of cases, respectively. At EOP, liver function tests were similar but creatinine clearance was higher in micafungin- vs standard care-treated patients. CONCLUSIONS: Micafungin was noninferior to standard care as antifungal prophylaxis in liver transplant patients at high risk for IFI. Adverse event profiles and liver function at EOP were similar, although kidney function was better with micafungin. CLINICAL TRIALS REGISTRATION: NCT01058174.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/cid/ciu1128

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 82

Metadata

Authors
Saliba, F., Pascher, A., Cointault, O., Laterre, P.-F., Cervera, C., De Waele, J. J., Cillo, U., Langer, R. M., Lugano, M., Göran-Ericzon, B., Phillips, S., Tweddle, L., Karas, A., Brown, M., Fischer, L., for the TENPIN (Liver Transplant European Study Into the Prevention of Fungal Infection) Investigators, Pratschke, J., Decruyenaere, J., De Waele, J. J., Laterre, P.-F., Moreno, C., Michielsen, P., Cointault, O., Fischer, L., Neuhaus, P., Pascher, A., Schemmer, P., Cervera, C., Varo, E., Montejo, M., Bouza, E., Blanes, M., De La Torre, J., Fortun, J., Saliba, F., Rostaing, L., Paugam-Burtz, C., Eyraud, D., Shah, T., Heaton, N., Langer, R. M., McCormick, A., Cillo, U., Salizzoni, M., Lugano, M., De Gasperi, A., Tomé, L., Daniel, J., Popescu, I., Moysyuk, Y. G., Chzhao, A. V., Zagaynov, V. E., & Ericzon, B.-G.
Venue
Clinical Infectious Diseases
Published
2014-12-17
Volume
60
Issue
7
Pages
997-1006
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
OpenAlex
W2132994229
Cited by
82
References
12
FWCI
4.11
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.